NETRIS Pharma

Executive Summary

NETRIS Pharma is a clinical-stage immuno-oncology company based in Lyon, France, founded in 2013. The company is pioneering first-in-class therapeutics that target Netrin-1, a neuronal guidance protein implicated in cancer progression and resistance to therapy. By blocking Netrin-1 signaling, NETRIS aims to overcome resistance to chemotherapy, targeted therapy, and immunotherapy across multiple solid tumors. Its lead candidate, NP137, is a monoclonal antibody currently being evaluated in Phase 1/2 clinical trials. The company operates as a unique integrated model within the Centre Léon Bérard and the Cancer Research Center of Lyon (CRCL), leveraging academic and clinical expertise to accelerate drug development. NETRIS Pharma represents a novel approach in immuno-oncology, addressing a key unmet need in patients who fail to respond to existing treatments.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 clinical data readout for NP137 in solid tumors60% success
• H1 2027Initiation of Phase 2/3 trial in a lead indication (e.g., pancreatic or colorectal cancer)50% success
• 2026Potential partnership or licensing deal with a larger pharmaceutical company40% success